This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.
Rainer Lipp, MD
Advertisement
Articles by Rainer Lipp, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas
2
Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma
3
Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?
4
Epcoritamab/Lenalidomide Significantly Improves PFS in R/R DLBCL
5